Gregory A. Korbel's most recent trade in Aprea Therapeutics Inc was a trade of 35,700 Stock Option (right to Buy) done . Disclosure was reported to the exchange on July 28, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aprea Therapeutics Inc | Gregory A. Korbel | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 35,700 | 35,700 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Gregory A. Korbel | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 24,300 | 45,762 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Gregory A. Korbel | Director, SVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.81 per share. | 03 Jun 2022 | 8,390 | 21,462 (0%) | 0% | 0.8 | 6,754 | Common Stock |
| Aprea Therapeutics Inc | Gregory A. Korbel | Director, SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 72,600 | 72,600 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Gregory A. Korbel | Director, SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 16,000 | 31,841 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Gregory A. Korbel | Director, SVP, Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.82 per share. | 10 Mar 2022 | 1,989 | 29,852 (0%) | 0% | 1.8 | 3,620 | Common Stock |
| Aprea Therapeutics Inc | Gregory A. Korbel | SVP, Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.74 per share. | 25 Feb 2022 | 1,326 | 15,841 (0%) | 0% | 1.7 | 2,307 | Common Stock |
| Aprea Therapeutics Inc | Gregory A. Korbel | SVP, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 27,500 | 25,245 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Gregory A. Korbel | SVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 4.89 per share. | 01 Oct 2021 | 27,500 | 17,167 (0%) | 0% | 4.9 | 134,475 | Common Stock |
| Aprea Therapeutics Inc | Gregory A. Korbel | SVP, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.92 per share. | 01 Oct 2021 | 27,500 | 44,667 (0%) | 0% | 0.9 | 25,300 | Common Stock |
| Aprea Therapeutics Inc | Gregory A. Korbel | SVP, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.92 per share. | 20 Sep 2021 | 27,500 | 44,667 (0%) | 0% | 0.9 | 25,300 | Common Stock |
| Aprea Therapeutics Inc | Gregory A. Korbel | SVP, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 27,500 | 52,745 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Gregory A. Korbel | SVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 4.97 per share. | 20 Sep 2021 | 27,500 | 17,167 (0%) | 0% | 5.0 | 136,675 | Common Stock |
| Aprea Therapeutics Inc | Gregory A. Korbel | SVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 4.98 per share. | 20 Sep 2021 | 5,460 | 17,167 (0%) | 0% | 5.0 | 27,191 | Common Stock |
| Aprea Therapeutics Inc | Gregory A. Korbel | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.59 per share. | 10 Sep 2021 | 1,724 | 22,627 (0%) | 0% | 4.6 | 7,913 | Common Stock |
| Aprea Therapeutics Inc | Gregory A. Korbel | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.98 per share. | 25 Aug 2021 | 1,149 | 24,351 (0%) | 0% | 4.0 | 4,573 | Common Stock |
| Aprea Therapeutics Inc | Gregory A. Korbel | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 15,000 | 25,500 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Gregory A. Korbel | VP of Business Devt | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 41,100 | 41,100 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Gregory A. Korbel | VP of Business Devt | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 10,000 | 10,500 (0%) | 0% | 0 | Common Stock |